Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-400 Topical Gel for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

NCT06262607 is registered in ClinicalTrials.gov with Clexio Biosciences Ltd. as lead sponsor.

NCT NCT06262607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06262607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-400 Topical Gel for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Lead sponsor
Clexio Biosciences Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 29, 2024
Completion date
November 19, 2024
Enrollment
59 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pruritus in adult subjects with notalgia paresthetica (np)